Description
Wilms Tumor 1 (WT1) serves as a pivotal transcription factor crucial for cellular development and survival. This gene encodes a tumor suppressor, whose inactivation has been linked to Wilms? tumor, implicating its involvement in WNT signaling by enhancing cytoplasmic beta-catenin (CTNNB1) degradation. Particularly expressed in mesenchymal-derived cells and Wilms? tumor, WT1 holds significance as a diagnostic marker for identifying malignant mesothelioma. A comprehensive literature review of 88 published papers revealed the utility of WT1 antibodies in identifying epithelioid mesothelioma, demonstrating a sensitivity of 77% and specificity of 96%. Beyond mesothelioma, WT1 immunoreactivity extends to various malignancies, including peritoneal serous carcinoma, breast, ovarian, and leukemia. In hepatocellular carcinoma, WT1 expression correlates with chemotherapy responsiveness, highlighting its prognostic value.
